Teligent Cites Remediation-Related Activites For Poor Quarter

As Company Recalls Lidocaine Anesthetic Solution Due To Super Potency

New Jersey-based Teligent reported a low quarter as the company continues to focus on remediation measures to lift the FDA warning letter hanging over its Buena New Jersey manufacturing facilty. Teligent has also recently recalled a batch of its 4% lidocaine hydrochloride topical solution because the firm’s testing found it to be super potent.

FDA
Teligent looks to remediate FDA warning letter in order to strengthen its injectables business • Source: Alamy

US-based Teligent saw its revenues drop to $10.4m in the second quarter of 2021, compared to $13.6m reported in the prior year period, with president and CEO Tim Sawyer citing a combination of factors for the underwhelming quarter including “remediation-related activities, the ongoing effects of the COVID-19 pandemic and modest generic pricing erosion seen within the topicals segment.”

However, the company indicated that it was exploring options to strengthen its injectables segment. “Looking ahead,” Sawyer said, “we are...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Generics

  • Amneal Kicks Off China Business With First Approval

    Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

  • Nichi-Iko Warns Over Delays From Toyama Plant

    Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.